Introduction {#s1}
============

Prostaglandin endoperoxide synthase 1 (*PTGS1*) and *PTGS2*, known as cyclooxygenase 1 (*COX1*) and *COX2*, catalyze the oxidative conversion of arachidonic acid to prostaglandin (PG) H~2~, which is subsequently metabolized to various biologically active metabolites, such as prostacyclin and thromboxane A~2~ [@pone.0071126-Smith1]. Although both *PTGS1* and *PTGS2* catalyze the same committed step in prostanoid biosynthesis with similar efficiencies, they are encoded by distinct genes located on different chromosomes, and they substantially differ in their expression pattern [@pone.0071126-Smith1]. *PTGS1* is constitutively expressed in most tissues and is responsible for the biosynthesis of PGs involved in various housekeeping functions, such as the regulation of renal, gastrointestinal, and platelet function [@pone.0071126-Smith1]. *PTGS2* is rapidly induced by growth factors, inflammatory cytokines, and tumor promoters [@pone.0071126-Prescott1], and it primarily catalyzes PG synthesis in cells involved in both local and systemic inflammatory responses [@pone.0071126-Smith1].

Inflammation increases the risk of several types of cancer, including colon, prostate, and pancreatic cancer [@pone.0071126-Prescott1], [@pone.0071126-Mantovani1]. Therefore, it is postulated that reducing inflammation might decrease the development of cancer. Nonsteroidal anti-inflammatory drugs (NSAIDs) inhibit *PTGS*-mediated PG synthesis and reduce inflammation. NSAIDs are popular medicines used worldwide for the prevention and/or treatment of various diseases. Several epidemiological studies have investigated whether NSAID use is correlated to a reduced risk of developing cancer; however, this is a debatable matter. Furthermore, it is suggested that genetic variation in *PTGS1* and *PTGS2* might be related to cancer risk and/or drug efficacy in humans. To date, several studies have investigated associations of the polymorphisms in the *PTGS1* and *PTGS2* genes and NSAID use on cancer risk; however, these studies have produced mixed results. Therefore, we performed a meta-analysis to determine the association between the polymorphisms in *PTGS1* and *PTGS2* and NSAID use on the risk of developing cancer.

Materials and Methods {#s2}
=====================

Literature Search {#s2a}
-----------------

We searched for publications in MEDLINE, EMBASE, Science Direct and the Cochrane Library by using the keywords and strategy terms "cyclooxygenase" or "*COX*" or "*PTGS*", "NSAID", "genotype" or "polymorphism", and "cancer" or "carcinoma" (last search was in March 2012). Non-controlled trials were excluded. Randomized controlled trials with three or more groups were retained if at least two groups addressed an eligible comparison.

Inclusion Criteria {#s2b}
------------------

Studies were chosen if the following criteria were provided: (1) full-text articles were written in English; (2) controlled trials comparing *PTGS* polymorphisms and the risk of developing cancer, including NSAID use status; (3) sufficient published data for estimating an odds ratio (OR) or relative risk with 95% confidence interval (CI); and (4) the numbers of case, control, NSAID users, and non-NSAID-users by *PTGS* genotypes were clarified. The following information was not considered as selective criteria: (1) blindness of the trial; (2) type of cancer; (3) type of NSAID; and (4) NSAID dose method.

Data Extraction {#s2c}
---------------

Data extraction was performed independently by two authors (Nagao and Sato) by using a standard protocol according to the criteria. The following data were extracted: the name of the first author, year of publication, country of research institution, type of cancer, study design, age, gender, and the number of cases and controls with NSAID users or non-users by genotype.

Statistical Analysis {#s2d}
--------------------

All statistical analyses were performed using the rmeta package for R, version 2.14.2 (The R Foundation for Statistical Computing, Tsukuba, Japan; <http://www.R-project.org>). Two-sided probability (*P*) values of \<0.05 were considered statistically significant. ORs with 95% CIs were calculated to assess the strength of the following associations: (1) between *PTGS* genotype with NSAID users and the risk of developing cancer, (2) between NSAID users homozygous for the major allele and the risk of developing cancer, (3) between *PTGS* genotype with non-NSAID users and the risk of developing cancer, and (4) between NSAID users with minor allele carriers and the risk of developing cancer.

All meta-analyses were appraised for inter-study heterogeneity by using χ^2^-based Q statistics for statistical significance of heterogeneity. If there was no heterogeneity based on a Q-test *P* value more than 0.05, a fixed-effect model using the Mantel-Haenszel (M-H) method was used. Otherwise, the random-effects model using the DerSimonian and Laird method was employed. Sensitivity analyses were performed to assess the stability of the results by sequential omission of individual studies. To evaluate the possible publication bias, Egger's test (linear regression method) and Begg's test (rank correlation method) were used, and *P* values of \<0.05 were considered representative of significant statistical publication bias.

Results {#s3}
=======

Characteristics of the Studies in Our Meta-analysis {#s3a}
---------------------------------------------------

A total of 51 relevant reports were initially identified. Thirty-eight of the 51 studies were excluded because they did not meet our criteria. Among the 38 excluded studies, 28 studies did not perform the analysis for recurring SNPs, and 10 studies did not provide the number of subjects to calculate for OR. Therefore, 13 of the 51 studies were included in the meta-analysis ([Fig. 1](#pone-0071126-g001){ref-type="fig"}). All of the studies were published in English. The characteristics of the selected studies are summarized in [Table 1](#pone-0071126-t001){ref-type="table"} and [Table S1](#pone.0071126.s001){ref-type="supplementary-material"}. The 13 studies analyzed the following polymorphism: *PTGS1* rs3842787 (n = 3) [@pone.0071126-Hubner1]--[@pone.0071126-Ulrich1], *PTGS2* rs5275 (n = 8) [@pone.0071126-Gallicchio1], [@pone.0071126-Lurie1]--[@pone.0071126-Vogel3], *PTGS2* rs20417 (n = 7) [@pone.0071126-Hubner1], [@pone.0071126-Andersen1]--[@pone.0071126-Gong1], [@pone.0071126-Vogel2], [@pone.0071126-Daraei1], [@pone.0071126-Ulrich2], *PTGS2* rs689466 (n = 3) [@pone.0071126-Andersen1], [@pone.0071126-Vogel1], [@pone.0071126-Vogel2], and rs2745557 (n = 3) [@pone.0071126-Gallicchio1], [@pone.0071126-Barry1], [@pone.0071126-Cheng1].

![The flow diagram of the literature search and the study selection.](pone.0071126.g001){#pone-0071126-g001}

10.1371/journal.pone.0071126.t001

###### Summary of articles included in the meta-analysis.

![](pone.0071126.t001){#pone-0071126-t001-1}

  Study                                                     Country        Outcome            Study design               Age                Gender            case     control            
  ------------------------------------------------------ -------------- -------------- -------------------------- ----------------- ----------------------- --------- --------- --------- ---------
  Hubner *et al*, 2007 [@pone.0071126-Hubner1]                 UK            CRA              cohort study           57.3 ± 9.3             289/256           8/66      8/55     20/186    30/173
  Gallicchio *et al*, 2006 [@pone.0071126-Gallicchio1]        USA             BC              cohort study              53.2         0/1467 (females only)    10/55     2/13     136/770   51/305
  Ulrich *et al*, 2004 [@pone.0071126-Ulrich1]                USA            CRA           case-control study           30-74           Without details      41/287    29/190    56/288    38/273
  *PTGS2* rs5275                                           TC+CC/ TT      TC+CC/ TT            TC+CC/ TT              TC+CC/ TT                                                           
  Lurie *et al*, 2010 [@pone.0071126-Lurie1]                  USA             OC           case-control study            ≥18         0/2454 (females only)   300/282   194/172   452/375   344/361
  Andersen *et al*, 2009 [@pone.0071126-Andersen1]          Denmark          CRC              cohort study              50-64               619/505          151/94     61/53    306/222   144/93
  Barry *et al*, 2009 [@pone.0071126-Barry1]                  USA            CRA              cohort study           57.6 ± 9.6             630/349           81/72    156/118   103/70    200/163
  Gong *et al*, 2009 [@pone.0071126-Gong1]                    USA            CRA           case-control study           30-74               168/205           84/50     14/14     96/54     46/15
  Vogel *et al*, 2008 [@pone.0071126-Vogel1]                Denmark           LC        nested case-cohort study        50-64               631/516          151/125    69/54    290/218   139/90
  Vogel *et al*, 2007 [@pone.0071126-Vogel2]                Denmark          BCC        nested case-cohort study        50-64               293/326          131/92     49/29    120/97     49/46
  Vogel *et al*, 2006 [@pone.0071126-Vogel3]                Denmark           BC        nested case-cohort study        50-64        0/712 (females only)     83/73    108/92     84/50    119/103
  Gallicchio *et al*, 2006 [@pone.0071126-Gallicchio1]        USA             BC              cohort study              53.2         0/1467 (females only)    37/29      5/9     511/396   198/158
  ***PTGS2*** **rs20417**                                 **GC+CC/GG**   **GC+CC/GG**         **GC+CC/GG**          **GC+CC/GG**                                                          
  Daraei *et al*, 2012 [@pone.0071126-Daraei1]                Iran           CRC           case-control study         58.2±14.8             117/113           64/31      8/7      47/44     19/10
  Andersen *et al*, 2009 [@pone.0071126-Andersen1]          Denmark          CRC              cohort study             50--64               619/505          65/180     27/87    131/397   68/169
  Barry *et al*, 2009 [@pone.0071126-Barry1]                  USA            CRA              cohort study            57.6±9.6              630/349          40/109    86/181    47/117    97/263
  Gong *et al*, 2009 [@pone.0071126-Gong1]                    USA            CRA           case-control study          30--74               168/205           45/89     9/19      60/90     24/37
  Hubner *et al*, 2007 [@pone.0071126-Hubner1]                 UK            CRA              cohort study            57.3±9.3              289/256           19/55     19/44    49/157    49/154
  Vogel *et al*, 2007 [@pone.0071126-Vogel2]                Denmark          BCC        nested case-cohort study       50--64               293/326          59/164     25/53    49/168     23/72
  Ulrich *et al*, 2005 [@pone.0071126-Ulrich2]                USA            CRA           case-control study          30--74           Without details      95/217    64/127    96/228    83/177
  ***PTGS2*** **rs689466**                                **AG+GG/AA**   **AG+GG/AA**         **AG+GG/AA**          **AG+GG/AA**                                                          
  Andersen *et al*, 2009 [@pone.0071126-Andersen1]          Denmark          CRC              cohort study             50--64               619/505          89/156     40/74    199/329   84/153
  Vogel *et al*, 2008 [@pone.0071126-Vogel1]                Denmark           LC        nested case-cohort study       50--64               631/516          90/186     49/74    194/314   81/148
  Vogel *et al*, 2007 [@pone.0071126-Vogel2]                Denmark          BCC        nested case-cohort study       50--64               293/326          79/144     25/53    91/126     42/53
  ***PTGS2*** **rs2745557**                               **GA+AA/GG**   **GA+AA/GG**         **GA+AA/GG**          **GA+AA/GG**                                                          
  Barry *et al*, 2009 [@pone.0071126-Barry1]                  USA            CRA              cohort study            57.6±9.6              630/349          50/105    89/187    59/113    114/255
  Cheng *et al*, 2007 [@pone.0071126-Cheng1]                  USA             PC           case-control study      Without details    1337/0 (males only)    64/264    78/413    80/144    108/186
  Gallicchio *et al*, 2006 [@pone.0071126-Gallicchio1]        USA             BC              cohort study              53.2         0/1467 (females only)    19/50     8/10     306/631   123/239

Abbreviations: No, non-NSAID users; Yes, NSAID users; PC, prostate cancer; CRC, colorectal cancer; OC, ovarian cancer; CRA, colorectal adenoma; LC, lung cancer; BCC, basal cell carcinoma; BC, breast cancer.

The Hardy-Weinberg equilibrium could not be estimated because the allele frequencies were not clarified in the literature.

Meta-analysis of the *PTGS1* Polymorphisms and NSAID Use on the Risk of Developing Cancer {#s3b}
-----------------------------------------------------------------------------------------

For *PTGS1* rs3842787, NSAID users homozygous for the major allele (CC) demonstrated a significantly decreased cancer risk compared with non-NSAID users ([Fig. 2A](#pone-0071126-g002){ref-type="fig"}, OR = 0.73, 95% CI = 0.59--0.89). However, there were no significant differences in the risk of developing cancer between NSAID users and non-NSAID users with minor allele carriers (CT+TT) ([Fig. 2B](#pone-0071126-g002){ref-type="fig"}, OR = 0.87, 95% CI = 0.52--1.46). There was no significant difference between homozygous for the major allele or carriers of the minor allele among non-NSAID ([Fig. 2C](#pone-0071126-g002){ref-type="fig"}, OR = 0.85, 95% CI = 0.60--1.19) or NSAID ([Fig. 2D](#pone-0071126-g002){ref-type="fig"}, OR = 1.01, 95% CI = 0.66--1.53) users. We did not detect any significant heterogeneity.

![Forest plot of the association between the *PTGS1* rs3842787 polymorphism and NSAID use on cancer risk.\
The difference in the development of cancer between NSAID use and non-NSAID use from individuals homozygous for the major allele (a), between NSAID use and non-NSAID use from individuals with minor allele carriers (b), between the non-NSAID users homozygous for the major allele and the minor allele carriers (c), and between the NSAID users homozygous for the major allele and the minor allele carriers (d). Squares represent study-specific ORs; horizontal lines represent 95% CIs; size of square reflects study-specific statistical weight (inverse of the variance); diamonds represent summary OR and 95% CI.](pone.0071126.g002){#pone-0071126-g002}

Meta-analysis of the *PTGS2* Polymorphisms and NSAID Use on the Risk of Developing Cancer {#s3c}
-----------------------------------------------------------------------------------------

For *PTGS2* rs5275, NSAID users significantly decreased the cancer risk compared with non-NSAID users homozygous for the major allele (TT) ([Fig. 3A](#pone-0071126-g003){ref-type="fig"}, OR = 0.77, 95% CI = 0.66--0.89). Similarly, NSAID users significantly decreased the cancer risk compared with non-NSAID users with the minor allele carriers (TC+CC) ([Fig. 3B](#pone-0071126-g003){ref-type="fig"}, OR = 0.84, 95% CI = 0.74--0.96). However, there were no associations with the *PTGS2* rs5275 polymorphism and NSAID use on the risk of developing cancer ([Fig. 3C, D](#pone-0071126-g003){ref-type="fig"}). Thus, the results of the meta-analysis among the 8 studies indicate that NSAID use significantly decreased cancer risk compared with non-NSAID use, despite the *PTGS2* polymorphism. In the stratified analysis by the type of cancer, there were no associations with colon cancer ([Fig. 3A--D](#pone-0071126-g003){ref-type="fig"}). However, NSAID users, in contrast to non-NSAID users, homozygous for the major allele, demonstrated a statistically significant decrease of cancers other than colon cancer ([Fig. 3A](#pone-0071126-g003){ref-type="fig"}, OR = 0.70, 95% CI = 0.59--0.83). In the subgroup analysis by locality, there were no associations among people of Denmark ([Fig. 4A--D](#pone-0071126-g004){ref-type="fig"}). In the USA, NSAID users, in contrast to non-NSAID users, homozygous for the major allele, demonstrated a statistically significant decrease of cancer. ([Fig. 4A](#pone-0071126-g004){ref-type="fig"}, OR = 0.67, 95% CI = 0.56--0.82). We did not detect any significant heterogeneity.

![Forest plot of the association between the *PTGS2* rs5275 polymorphism and NSAID use on cancer risk stratified by the type of cancer and overall incidence of cancer.\
The difference in the development of cancer between NSAID users and non-NSAID users homozygous for the major allele (a), between NSAID users and non-NSAID users with minor allele carriers (b), between the non-NSAID users homozygous for the major allele and the minor allele carriers (c), and between the NSAID users homozygous for the major allele and the minor allele carriers (d). Squares represent study-specific ORs; horizontal lines represent 95% CIs; size of square reflects study-specific statistical weight (inverse of the variance); diamonds represent summary OR and 95% CI.](pone.0071126.g003){#pone-0071126-g003}

![Forest plot of the association between the *PTGS2* rs5275 polymorphism and NSAID use on cancer risk stratified by ethnicity.\
The difference in the development of cancer between NSAID users and non-NSAID users homozygous for the major allele (a), between NSAID users and non-NSAID users with minor allele carriers (b), between the non-NSAID users homozygous for the major allele and the minor allele carriers (c), and between the NSAID users homozygous for the major allele and the minor allele carriers (d). Squares represent study-specific ORs; horizontal lines represent 95% CIs; size of square reflects study-specific statistical weight (inverse of the variance); diamonds represent summary OR and 95% CI.](pone.0071126.g004){#pone-0071126-g004}

For *PTGS2* rs20417, NSAID use significantly decreased cancer risk compared with non-NSAID use in individuals homozygous for the major allele (GG) ([Fig. 5A](#pone-0071126-g005){ref-type="fig"}, OR = 0.82, 95% CI = 0.70--0.95). Similarly, NSAID use significantly decreased cancer risk compared with non-NSAID use in individuals with the minor allele carriers (GC+CC) ([Fig. 5B](#pone-0071126-g005){ref-type="fig"}, OR = 0.78, 95% CI = 0.62--0.98). However, there were no associations with the risk of developing cancer with NSAID use and the *PTGS2* rs20417 polymorphism ([Fig. 5C, D](#pone-0071126-g005){ref-type="fig"}). Thus, the results of the meta-analysis among the 7 studies also indicate that NSAID use significantly decreased cancer risk compared with non-NSAID use, regardless of the *PTGS2* polymorphism. In the stratified analysis by the type of cancer, NSAID users, in contrast to non-NSAID users, homozygous for the major allele or carriers of the minor allele, demonstrated a statistically significantly decrease in colon cancer risk ([Fig. 5A](#pone-0071126-g005){ref-type="fig"}, OR = 0.83, 95% CI = 0.70--0.97; [Fig. 5B](#pone-0071126-g005){ref-type="fig"}, OR = 0.77, 95% CI = 0.61--0.98, respectively). In the subgroup analysis by locality, there were no associations among people from Denmark ([Fig. 6A--D](#pone-0071126-g006){ref-type="fig"}). In the USA, NSAID users, in contrast to non-NSAID users, homozygous for the major allele demonstrated a statistically significant decrease of cancer ([Fig. 6A](#pone-0071126-g006){ref-type="fig"}, OR = 0.72, 95% CI = 0.58--0.88).

![Forest plot of the association between the *PTGS2* rs20417 polymorphism and NSAID use on cancer risk stratified by the type of cancer and overall incidence of cancer.\
The difference in the development of cancer between NSAID users and non-NSAID users homozygous for the major allele (a), between NSAID users and non-NSAID users with minor allele carriers (b), between the non-NSAID users homozygous for the major allele and the minor allele carriers (c), and between the NSAID users homozygous for the major allele and the minor allele carriers (d). Squares represent study-specific ORs; horizontal lines represent 95% CIs; size of square reflects study-specific statistical weight (inverse of the variance); diamonds represent summary OR and 95% CI.](pone.0071126.g005){#pone-0071126-g005}

![Forest plot of the association between the *PTGS2* rs20417 polymorphism and NSAID use on cancer risk stratified by ethnicity.\
The difference in the development of cancer between NSAID users and non-NSAID users homozygous for the major allele (a), between NSAID users and non-NSAID users with minor allele carriers (b), between the non-NSAID users homozygous for the major allele and the minor allele carriers (c), and between the NSAID users homozygous for the major allele and the minor allele carriers (d). Squares represent study-specific ORs; horizontal lines represent 95% CIs; size of square reflects study-specific statistical weight (inverse of the variance); diamonds represent summary OR and 95% CI.](pone.0071126.g006){#pone-0071126-g006}

For *PTGS2* rs689466 and rs2745557, we found that there were no associations between the risk of developing cancer and NSAID use and polymorphisms ([Fig. 7A--D](#pone-0071126-g007){ref-type="fig"} and [Fig. 8A--D](#pone-0071126-g008){ref-type="fig"}).

![Forest plot of the association between the *PTGS2* rs689466 polymorphism and NSAID use on cancer risk.\
The difference in the development of cancer between NSAID users and non-NSAID users homozygous for the major allele (a), between NSAID users and non-NSAID users with minor allele carriers (b), between the non-NSAID users homozygous for the major allele and the minor allele carriers (c), and between the NSAID users homozygous for the major allele and the minor allele carriers (d). Squares represent study-specific ORs; horizontal lines represent 95% CIs; size of square reflects study-specific statistical weight (inverse of the variance); diamonds represent summary OR and 95% CI.](pone.0071126.g007){#pone-0071126-g007}

![Forest plot of the association between the *PTGS2* rs2745557 polymorphism and NSAID use on cancer risk.\
The difference in the development of cancer between NSAID users and non-NSAID users homozygous for the major allele (a), between NSAID users and non-NSAID users with minor allele carriers (b), between the non-NSAID users homozygous for the major allele and the minor allele carriers (c), and between the NSAID users homozygous for the major allele and the minor allele carriers (d). Squares represent study-specific ORs; horizontal lines represent 95% CIs; size of square reflects study-specific statistical weight (inverse of the variance); diamonds represent summary OR and 95% CI.](pone.0071126.g008){#pone-0071126-g008}

Sensitivity Analyses {#s3d}
--------------------

For *PTGS1* rs3842787, sensitivity analyses indicated that the results of one independent study by Ulrich *et al*. [@pone.0071126-Ulrich1] affected our original results considerably, and inclusion of this study was primarily responsible for the significant difference observed in the risk of cancer development between NSAID users and non-NSAID users homozygous for the major allele. For *PTGS2* rs5275, sensitivity analyses indicated that inclusion of the independent study by Lurie *et al*. [@pone.0071126-Lurie1] was primarily responsible for the significant difference observed in the risk of cancer development between NSAID users and non-NSAID users homozygous for the major allele in the overall group, cancer subgroups other than colon cancer, and the USA subgroup. Similarly, inclusion of the independent study by Barry *et al*. [@pone.0071126-Barry1] was mainly responsible for our original results in which no associations were observed between gene polymorphism and the risk of cancer development among NSAID users in the colon cancer subgroup. For *PTGS2* rs20417, sensitivity analyses indicated that inclusion of the independent studies by Barry *et al*. [@pone.0071126-Barry1], Gong *et al*. [@pone.0071126-Gong1], and Ulrich *et al*. [@pone.0071126-Ulrich2] was responsible for the significant difference observed in the risk of cancer development between NSAID users and non-NSAID users homozygous for the major allele in the colon cancer subgroup. In addition, inclusion of independent studies by Daraei *et al*. [@pone.0071126-Daraei1], Gong *et al*. [@pone.0071126-Gong1], and Ulrich *et al*. [@pone.0071126-Ulrich2] was found to be primarily responsible for the significant difference in the risk of cancer development between NSAID users and non-NSAID users with minor allele carriers in the overall group and the colon cancer subgroup. For *PTGS2* rs689466, sensitivity analyses indicated that inclusion of the independent study by Andersen *et al*. [@pone.0071126-Andersen1] was mainly responsible for our original results in which no associations were observed between gene polymorphism and the risk of cancer development among non-NSAID users. For *PTGS2* rs2745557, sensitivity analyses indicated that the results of one independent study by Cheng *et al*. [@pone.0071126-Cheng1] were primarily responsible for no significant difference being observed in the risk of cancer development between NSAID users and non-NSAID users homozygous for the major allele. These results suggest that a limited number of studies could substantially influence the ORs.

Publication Bias {#s3e}
----------------

Begg's test and Egger's test were performed to estimate the publication bias of the literature ([Table 2](#pone-0071126-t002){ref-type="table"}). Egger's test did not indicate any evidence of potential publication bias; Begg's test indicated that publication biases generally have no significant effect on the results of overall analysis, except for the association between the *PTGS2* rs5275 polymorphism and NSAID users (P = 0.026), which was most likely due to the limited number of studies on *PTGS2* rs5275 polymorphism.

10.1371/journal.pone.0071126.t002

###### Egger's and Begg's test to measure the funnel plot asymmetric.

![](pone.0071126.t002){#pone-0071126-t002-2}

  Polymorphisms                                                                  
  ------------------- ----------------- -------------------- ------------------- --------------------
  P~E~                      0.987              0.075                0.101               0.527
  P~B~                      0.602              0.117                0.117               0.602
  *PTGS2* rs5275       No vs. Yes (TT)   No vs. Yes (TC+CC)   TT vs. TC+CC (No)   TT vs. TC+CC (Yes)
  P~E~                      0.415              0.071                0.844               0.066
  P~B~                      0.458              0.322                1.000             **0.026**
  *PTGS2* rs20417      No vs. Yes (GG)   No vs. Yes (GC+CC)   GG vs. GC+CC (No)   GG vs. GC+CC (Yes)
  P~E~                      0.622              0.183                0.604               0.313
  P~B~                      0.881              0.293                0.652               0.293
  *PTGS2* rs689466     No vs. Yes (AA)   No vs. Yes (AG+GG)   AA vs. AG+GG (No)   AA vs. AG+GG (Yes)
  P~E~                      0.847              0.150                0.680               0.155
  P~B~                      0.602              0.117                0.602               0.117
  *PTGS2* rs2745557    No vs. Yes (GG)   No vs. Yes (GA+AA)   GG vs. GA+AA (No)   GG vs. GA+AA (Yes)
  P~E~                      0.379              0.065                0.431               0.768
  P~B~                      0.117              0.117                0.602               0.602

Abbreviations: No, non-NSAID users; Yes, NSAID users; P~E~: P for Egger's test, P~B~; P for Begg's test.

The bold value indicates a potential publication bias.

Discussion {#s4}
==========

In the current study, we searched the literature to determine the association between *PTGS1* or *PTGS2* polymorphisms and NSAID use on the risk of developing cancer. Although many SNPs located in the region of *PTGS1* are known, 1 polymorphism (rs3842787) was analyzed by 3 independent researchers to determine whether the gene polymorphism and NSAID use is associated with cancer risk. Ulrich *et al*. [@pone.0071126-Ulrich1] reported that NSAID use by individuals with the wild type polymorphism of *PTGS1* rs3842787 had a significantly reduced ([Fig. 2A](#pone-0071126-g002){ref-type="fig"}, OR = 0.70, 95% CI = 0.55--0.89) adenoma risk compared with non-NSAID users. However, Gallicchio *et al*. [@pone.0071126-Gallicchio1] and Hubner *et al*. [@pone.0071126-Hubner1] reported that there was no association between the *PTGS1* rs3842787 polymorphism and NSAID use on the development of cancer. Our meta-analysis showed that the NSAID users had a lower risk of developing cancer compared with the non-NSAID users among individuals homozygous for the major allele of *PTGS1* rs3842787. The rs3842787 SNP is located in exon 2 of *PTGS1*, and causes the substitution of a leucine for a proline at codon 17 (P17L). These results suggest that the *PTGS1* rs3842787 non-synonymous polymorphism may be an important pharmacogenomic biomarker.

For *PTGS2*, there have been studies of 4 SNPs (rs5275, rs20417, rs689466, and rs2745557), which were analyzed for an association with cancer risk and NSAID use; however, the studies have produced mixed results. The rs5275 SNP is located in exon 10 (3′-untranslated region: 3′-UTR) of the *PTGS2* gene, which is downstream of the stop codon, and the C allele has been associated with lower steady-state *PTGS2* mRNA levels [@pone.0071126-Lurie1]. The rs20417 SNP is located in the promoter region of the *PTGS2* gene. The C variant allele of the rs20417 has significantly lower promoter activity than the G allele [@pone.0071126-Gong1]. In a recent meta-analysis study, the rs20417 emerged to be an influential SNP on colorectal cancer risk in the Asian population [@pone.0071126-Cao1]. The rs689466 SNP is also located in the promoter region of the *PTGS2* gene. The A allele of the rs689466 has been associated with strikingly higher promoter activity [@pone.0071126-Zhang1]. Dong *et al*. [@pone.0071126-Dong1] reported that the A allele of rs689466 was significantly associated with increased risk of digestive system cancers. The location of these polymorphisms on the gene promoter region would directly influence the regulation of gene expression and the rate of enzyme production [@pone.0071126-Daraei1]. Therefore, it is considered that these polymorphisms, in conjunction with NSAID use, have an influence on cancer risk; however, our meta-analysis did not detect associations in any group. On the other hand, we found that the associations between *PTGS2* polymorphisms and NSAID use on cancer risk differ by the type of cancer and ethnicity. Because *PTGS2* is not constitutively expressed in tissues but is induced by growth factors, inflammatory cytokines, and tumor promoters, the effect of NSAIDs on *PTGS2* may differ by tissues. Furthermore, Zhang *et al*. [@pone.0071126-Zhang2] found that the haplotype of *PTGS2* including rs20417 and rs689466 SNP was associated with gastric cancer in Chinese populations, which indicates the necessity to study haplotypes.

In these studies, the types of NSAIDs (e.g., aspirin, ibuprofen, and other NSAIDs), dose methods (e.g., dosage and duration), study design (e.g., case control study or cohort study), population (e.g., age, gender, type of cancer, and ethnic), and study power are different. In addition, there was the lack of specificity for cancer type in our analysis because few studies have investigated the effect of associations between polymorphisms in *PTGS1* and *PTGS2* genes and NSAID use on cancer risk. Thus, it is difficult to draw any conclusion about the relationship between *PTGS* genotype and NSAID use on the risk of developing cancer. Nonetheless, our results provide limited evidence. Drug response is a complex phenomenon dependent on inherited and environmental factors. To carry more credibility, further analyses with study design formulation are required in several countries.
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